Xeris announced a collaboration and licensing agreement with Beta Bionics. The agreement involves developing and commercializing a glucagon product using Xeris’ XeriSol™ technology for Beta Bionics’ proprietary bi-hormonal pump system for diabetes management.

“We’re thrilled to partner with Beta Bionics as the exclusive provider of the glucagon component for their groundbreaking dual-hormone pump,” said Xeris Chairman and CEO Paul R. Edick. “We’ll be working swiftly to support Beta Bionics in this crucial development program.”

“Glucagon acts like the brakes in a car, regulating blood sugar alongside insulin, which is like the gas pedal,” explained Beta Bionics CEO Sean Saint. “For a long time, Beta Bionics has believed that a bi-hormonal glucose control system offers significant advantages over insulin alone. This partnership with Xeris allows us to take a major step towards bringing this system to market.”

The licensing agreement offers Xeris potential development payments along with royalties on future sales of the glucagon product for Beta Bionics’ pumps.

Read the press release

X